Male sex and advanced age associated with higher risk of RP-ILD in anti-MDA5 dermatomyositis patients.

A systematic review and meta-analysis synthesized data from 15 studies to identify clinical factors associated with the occurrence of rapidly progressive interstitial lung disease (RP-ILD) in patients with anti-MDA5 antibody-positive dermatomyositis. The analysis focused on demographic and clinical characteristics rather than specific pharmacological interventions, as no medications were reported in the input data. The setting and follow-up duration for the included studies were not reported.

The meta-analysis found that male sex was associated with an increased risk of RP-ILD, with an odds ratio of 1.99 (95% CI: 1.27-3.12). Similarly, advanced age was associated with a higher risk, yielding an odds ratio of 2.54 (95% CI: 1.40-4.60). Absolute numbers for these outcomes were not reported in the source data. No other factors were identified as significant predictors in the provided results.

Safety data, including adverse events, serious adverse events, discontinuations, and tolerability, were not reported for the interventions or exposures evaluated. The study phase was not reported, and funding or conflicts of interest were not disclosed. Key limitations regarding the certainty of the evidence and specific constraints of the included studies were not detailed in the input.

Given the observational design and lack of reported causality, these associations should be interpreted as risk markers rather than proven causes. Clinicians may consider these factors when assessing the risk of RP-ILD in anti-MDA5 dermatomyositis patients, but further research is needed to confirm these relationships and guide management strategies.